Association of Immune-Related Genetic and Epigenetic Alterations with Lupus Nephritis

Xiaole Mei a, b, c, d, e  Hui Jin d, e  Ming Zhao d, e  Qianjin Lu a, b, c, d, e

a Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China; b Key Laboratory of Basic and Translational Research on Immunological Dermatology, Chinese Academy of Medical Sciences, Nanjing, China; c Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China; d Hunan Key Laboratory of Medical Epigenomics, Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China; e Research Unit of Key Technologies of Diagnosis and Treatment for Immune-related Skin Diseases, Chinese Academy of Medical Sciences, Changsha, China

Keywords
Lupus nephritis · Systemic lupus erythematosus · Genetics · Epigenetics · Immune system

Abstract

Background: The familial clustering phenomenon together with environmental influences indicates the presence of a genetic and epigenetic predisposition to systemic lupus erythematosus (SLE). Interestingly, regarding lupus nephritis (LN), the worst complication of SLE, mortality and morbidity were not consistent with SLE in relation to sexuality and ethnicity. Summary: Genetic and epigenetic alterations in LN include genes and noncoding RNAs that are involved in antigen-presenting, complements, immune cell infiltration, interferon pathways, and so on. Once genetic or epigenetic change occurs alone or simultaneously, they will promote the formation of immune complexes with autoantibodies that target various autoantigens, which results in inflammatory cytokines and autoreactive immune cells colonizing renal tissues and contributing to LN. Key Messages: Making additional checks for immunopathology-related heredity and epigenetic factors may lead to a more holistic perspective of LN.

Introduction

The onset of systematic lupus erythematosus (SLE) is insidious, and the etiology is complex. As one of the most common complications, lupus nephritis (LN) can be manifested by proteinuria, hematuria, hypertension, edema, etc. Eugeniu et al. [1] reported that up to 6.3% of patients died within 5 years after their diagnosis of LN, a percentage which has remained stable over the last three decades despite the reduction of clinical severity in recent years [2]. In detail, according to a 2003 histological classification made by the International Society of Nephrology/Renal Pathology Society (ISN/RPS) based on microscopic lesions and immune complexes (ICs) observed in a kidney biopsy, Class III and IV LN (proliferative LN) now account for 50% and 25% of the prevalence, respectively, with the worst prognosis to end-stage renal disease (ESRD) and in urgent need of immunosuppressive treatment [3].

The progression of LN is associated with pregnancy, aging, and drug-induced nephrotoxicity. It is worth noting that the incidence of SLE across gender is approximately 9:1 (female: male). However, the incidence of LN is somewhere between 1.1:1 and 1.7:1 by male to female ratio [4]. In addition, younger people, as well as ethni-
Aberrant Immune-Related Genetic and Epigenetic Alterations in LN

Culturally Asian, African, or Hispanic patients, seem to have a higher probability of developing LN compared with white individuals, indicating that genetic and epigenetic alterations in LN patients may vary from those of SLE patients.

With an increasing number of targeted therapy drugs approved by the FDA, immune cell-targeting agents such as belimumab have become the new hope for SLE patients who have poor responses to glucocorticosteroids, cyclophosphamide, and other immunosuppressive agents, whereas none for LN to date [5]. In this regard, we hope to dig more possible immunotargets which are responsible for this lethal outcome of SLE instead of angiogenesis and fibrosis, which are the common targets for other kidney diseases. Moreover, we have summarized the aberrant genetic and epigenetic changes in LN immunopathology, which may pave the way for monitoring and management in the future.

**Immune Mechanisms in the Pathogenesis of LN**

As for the mechanism of SLE onset, much of the previous research has shown that the increase of autoreactive T and B cells as well as apoptotic debris in circulation are indispensable. We therefore see no need to discuss these processes at length here. However, due to the difference in cell components, target organ damage in lupus has a different pathophysiology and pathogenesis. Key points relating to immune mechanisms in LN flares are listed below and compiled in Figure 1.

**Autoantibodies, ICs, and Complements**

Although not all of the observed lupus patients had LN, almost all patients had deposition of ICs in the mesangial region [6], primarily IgG derived. In the past, ds-DNA antibodies in serums have served as a strong indicator of renal damage for lupus. Some ICs originate from...
circulation, while planted [7] and locally distributed autoantigens such as α-enolase and annexin A1 attract anti-DNA antibodies to form IC and deposits further in the glomerular basement membrane, which constitute another part of kidney IC. Complements and cells expressing Fc receptors (FcyRs), a receptor for IgG, will then be activated to clear ICs. Excessive myeloid cells [6, 8] and platelets [9] bearing stimulatory FcyRs in LN, which can also be potentiated by a complement, will degranulate and release reactive oxygen species. Finally, immune cells are recruited leading to damage of the endothelial and epithelial cells and renal fibrosis.

The Infiltration of Innate Immune Cells

Macrophages are the dominant immune cells in the kidney and include the resident cells in the renal interstitium as well as the infiltrating cells around the glomeruli [10]. Macrophage migration-related cytokines such as monocyte chemotactic protein 1 and macrophage migration inhibitory factor are secreted by damaging tubular cells and have been deemed one of the markers of LN. Trajectory analysis of monocytes/macrophages within the kidney suggested that patrolling, phagocytic, and activated monocytes were present in the progressive stages of monocyte differentiation in situ [10]. Generally, macrophages are thought to play different roles in their inflammation and repair states, M1 and M2, respectively. M1 secretes inflammatory cytokines and is skewed by Toll-like receptors (TLRs) and danger-associated molecular patterns [11]. A noteworthy observation is that TLRs not only directly influence macrophages but also facilitate the renal endothelium to recruit monocytes [12]. Previous studies have observed increasing expression of TLR 3, 7/8, 9, both in the mouse model and in human renal biopsies of LN [13].

After neutrophils are activated by FcyRs and produce reactive oxygen species, neutrophil extracellular traps containing DNA, histone, MMP9, and other nuclear materials release and promote type I interferons (IFN-I) produced mainly by plasmacytoid dendritic cells (pDCs) [14]. Apoptotic debris taken up by DCs can be further lysed into single-stranded or double-stranded DNA/RNA (ssDNA/RNA, dsDNA/RNA). Unrestricted DNA and RNA in the cytosol is a dangerous signal and can be sensed by specific sensors such as TLRs, cyclic GMP-AMP synthetase (cGAS), or melanoma differentiation-associated gene 5 (MDA5), which results in activation of downstream IFN-regulatory factor 3 (IRF3)–IRF7 to produce IFN-I [15, 16]. Multiple articles have illustrated that abnormal expression of interferon-stimulated genes in SLE such as MX1 [17] and IFI44L [15, 18, 19] is related to the severity of LN flares. More importantly, a high IFN-response signature in tubular cells is even associated with poor treatment efficacy [20].

The Infiltration of Adaptive Immune Cells

T and B cells are often present in crescentic glomerulonephritis. Aggregations of T and B cells are tightly associated with low levels of estimated glomerular filtration rate and renal tubular function [21]. With the advent of single-cell techniques, the transcriptome of immune cells in lupus-affected kidneys has been shown to be distinct from those of the peripheral circulatory system. Recent research reveals that compared to excessive plasma cells in the peripheral blood, not only B cells in the kidneys are differentiated to plasma cells but also that activation of local B cells is more likely to correlate with the expression of the BCR/TLR signaling-mediated age-associated B-cell (ABC) signature [10]. In terms of T cells and follicular helper T cells (Tfh), a B-cell helper, which are all differentiated from naive CD4+ T cells, is believed to contribute to the severity of LN [10, 22]. Interestingly, markers of Tfh and Treg cells like PDCD1 and FOXP3 were found to be co-clustered in situ, suggesting T follicular regulatory cells (Tfr) may also be present and protect the kidney from damage [10].

Genetic Risk of LN

It is postulated that the risk of SLE is determined by the amount of risk-associated single nucleotide polymorphisms (SNPs) and their log odds ratios, which can be summarized by a genetic risk score (GRS) [23]. Studies have been increasingly devoted to research on the relationship of GRS with SLE’s occurrence, manifestation, severity, and prognosis. Among the many SLE clinical phenotypes, only LN has been specially designated as being genetically associated and observed to have significant differences in outcome based on a patient’s racial background. Chen et al. [23] recently reported that GRS could predict SLE in both European and Chinese populations and correlates with a younger age-of-onset, LN, and poorer prognosis, consistent with findings of Reid et al. [24] and Dominguez et al. [25]. In Europeans, the associations between high GRS and LN even increased when narrowing cases to adult-onset, proliferative LN, or ESRD [25].
Major Histocompatibility Complex Loci

The present evidence indicates a super-hot spot, the human major histocompatibility complex (MHC) region, which is located on a segment of chromosome 6 (6p21.3). This region, about 25–32 Mb and responsible for encoding more than 200 genes many of them with a specific immunological role, participates in the development of autoimmunity, infection, and transplantation [26]. Previous studies have demonstrated that the heterogeneity in this region is its most established characteristic and it exists in almost all SLE and LN patients regardless of ethnicity [27, 28]. Among several MHC haplotypes, HLA DR2 (HLADRB1*1501, DQA1*0102, and DQB1*0602) and HLA DR3 (DRB1*0301, DQA1*0501, and DQB1*0201) which are primarily located in MHC class II, were the most frequently reported [29–31]. Prithvi et al. [30] showed that the risk haplotype of HLA-D induces higher surface expression of HLA II after activation of TLR pathways and the differentiation of DCs. Meanwhile, to lessen linkage disequilibrium influence, the GWAS study also showed that HCG27, located in the MHC class I region, which is independent of HLA-DR2 and HLA-DR3, is associated with LN [29]. In addition, HLA-DR4 and DR11 alleles were identified as protective factors for LN [32]. Several studies also revealed that polymorphism in the tumor necrosis factor (TNF) gene in this region is linked toLN susceptibility [33, 34].

Non-MHC Loci

As an initial factor in complement activation, C1q plays an important role in LN. C1q-deficient mice could develop LN-like phenotypes [35], while anti-C1q IgG2 can be detected in renal biopsies of up to 70% LN patients [7]. C1q-encoded genes, C1QA, C1QB, and C1QC, are located at chromosome 1p34.1–36. According to the genotype of C1QA polymorphism, the G allele for rs665691 and A allele for rs172378 were protective against nephritis [36, 37], while the A allele of rs292001 seems to be the risk factor for juvenile LN in Egypt [38].

APOL1 risk variants, the G1 (rs73885319 and rs60910145) and G2 (rs71785313) alleles, are tightly correlated only with LN and not with SLE patients, especially for African Americans and ESRD [39]. Notably, the time to ESRD progression is even shorter in those with 2 risk alleles [39]. APOL1 encodes apolipoprotein L-1, which is an abundant component in high-density lipoproteins. Apart from LN, SNPs are also represented in patients with virus-associated collapsing focal segmental glomerulosclerosis [40]. Furthermore, TLR3, IFN, and related cellular sensors such as RIG-I and cGAS could possibly upregulate APOL1 expression. This indicates APOL1’s role in innate immunity and antiviral activities. Functional studies also show that APOL1 risk variants confer autophagic deficiency but increased pyroptosis in podocytes [41].

Other findings have also revealed the significance of non-MHC loci (shown in Table 1). Most of them are related to the following vital pathways of LN [6, 42]: complements, phagocytosis, the clearing of ICs (FCGR2B [43], FCGR3B [43], FCGR2A [43], FCGR3A [44], PADI4 [45]), interferon pathways (IRF5 [46], STAT4 [24, 47, 48], IFN3/4 [49], etc.), T and B cell development and signaling (TNFSF4 [42], TL1A [50], IKZF1 [51]), etc. There were also some protective haplotypes in non-MHC regions, such as ACA of P2X7R gene [52] and GTTCTAA of CD40 gene [53]. In a research study conducted with a sample of 109 Korean LN patients (classes III–V), poor responses to cyclophosphamide were related to polymorphisms in the FCGR2B-FCRLA (1q23) locus [54]. Chung et al. [29] integrated 3 large GWAS studies and reported the prevalence of several independent susceptibility genes, such as chemotaxis-related HAS2 and apoptosis-related SLC5A11, which provide even stronger directionality to LN patients compared to lupus patients without nephritis in unrelated European women than the MHC region.

TLRs express both in immune (antigen-representing cells and B cells) and nonimmune cells (endothelial cells, renal mesangial cells). They function by sensing different pathogen-associated molecular patterns and activating downstream JAK/STAT and NF-κB pathways to release cytokines. TLR3, TLR7/8, and TLR9 are the receptors of dsRNA, ssRNA, and unmethylated ss-DNA, respectively. SNPs located at TLR3 rs3775291 and rs3775294 [55], TLR7 rs3853839 [55, 56], TLR9 rs352139 [57], and rs352140 [57, 58]. However, some studies also pointed out that the genetic change among TLRs correlates with SLE but not with LN [59–61]. The occurrence of genetic alterations in TLRs with LN is still controversial.

Epigenetic Risk of LN

The environment–gene interaction is usually linked by a bridge, epigenetics. Epigenetics refers to an alteration that occurs on a chromosome without altering the DNA sequence. DNA methylation, chromatin remodeling through histone modifications, and noncoding RNAs (ncRNAs) are the three most extensively studied and
best-characterized epigenetic processes, while our understanding of RNA methylation (RNAm) is emerging only now. Epigenetic changes could happen in PBMCs, serum/plasma, urine, renal tissues, etc. Different stages of disease progress represent different epigenetic changes. For example, hypermethylation was observed in pDCs of severe LN patients, while H3K4me3 and H3K27me3 were markedly decreased in the early stage of LN [62], indicating the possible roles of epigenetics in the precise diagnosis and treatment of lupus.

### DNA and RNA Methylation

Global levels of DNA hypomethylation in the T cells have long been recognized as characteristics of lupus and other autoimmune diseases. Among all the targeted genes, interferon-stimulated genes were the most frequently reported. More importantly, our group reported the hypomethylation of two CpG sites located in the promoter region of IFI44L as biomarkers for diagnosing SLE with high sensitivity and specificity (both above 95%) [19]. We found that the methylation levels of IFI44L pro-

---

**Table 1. Immunogenetics of LN**

| Locus | Location | SNP | Method | Ancestry | Reference |
|-------|----------|-----|--------|----------|-----------|
| **(A) MHC region** | | | | | |
| C6orf10, NOTCH4 | 6p21.32 | rs9267972 | GWAS | European women | [29] |
| HLA-DRB1*1501 | 6p21.32 | rs9271366 | GWAS | European women | [29] |
| HLA-DRB1*0301 | 6p21.32 | rs2187668 | GWAS | European women | [29] |
| HCG27 | 6p21.33 | rs9263871 | GWAS | European women | [29] |
| TNF | 6p21.33 | rs1800629 | TaqMan SNP genotyping | Chinese | [34] |
| | | rs1800750 | TaqMan SNP genotyping | Mexican | [33] |
| **(B) Complements, ICs, and phagocytosis** | | | | | |
| FCGR2B-FCRLA | 1q23.3 | rs6697139, rs10917686, rs10917688 | GWAS | Korean | [54] |
| FCGR3A | 1q23.3 | rs115866423 | Pyrosequencing | African American | [44] |
| FCGR2B | 1q23.3 | Haplotype 2B.4 (negative association) | Multiplex ligation-dependent probe amplification | Caucasian | [43] |
| C1QA | 1p36.12 | rs292001 | RFLP SNP genotyping | Egyptian children | [38] |
| | | rs172378 | TaqMan SNP genotyping | Bulgarian | [37] |
| ITGAM | 16p11.2 | rs1143679 | Illumina custom bead system | European | [42] |
| | | rs1143679, rs1143683 | GWAS | Chinese and Thai | [111] |
| **(C) Monocytes, T-, and B-cell development and signaling** | | | | | |
| HAS2 | 8q24.12 | rs7834765 | GWAS | European women | [29] |
| TNFSF4 | 1q25.1 | rs2205960 | Illumina custom bead system | European | [42] |
| MCP-1 | 17q12 | A-2518G | RFLP SNP genotyping | Brazilian | [100] |
| IKZF1 | 7p12.2 | rs1456896 | TaqMan SNP genotyping | Chinese | [51] |
| | | rs4917014 | GWAS | Chinese | [101] |
| **(D) Interferon pathways** | | | | | |
| IFNL3/4 | 19q13.2 | rs8099917, rs12979860, rs4803217, ss469415590 | TaqMan SNP genotyping | Chinese | [49] |
| STAT4 | 2q32.2-q32.3 | rs7574665 | GoldenGate SNP genotyping | Japanese women | [47] |
| | | | GWAS | European | [48] |
| IRF3 | 19q13.33 | rs7251 | GWAS | Chinese | [102] |
| APOL1 | 22q12.3 | rs73885319, rs60910145, rs71785313 | GWAS | African American | [39] |
| **(E) Neutrophil activation** | | | | | |
| PADI4 | 1p36.13 | rs1635564, rs11203366, rs11203367, rs874881, rs2240340, rs11203368 | In-house multiplex luminex assay | Danish | [45] |
| IL-8 | 4q13.3 | 845C | RFLP SNP genotyping | African American | [103] |
| **(F) Cell apoptosis** | | | | | |
| SLCSA11 | 16p12.1 | rs274068 | GWAS | European women | [29] |
| P2X7R | 1q24 | rs2230911 | TaqMan SNP genotyping | Chinese | [52] |
| MCP-1, monocyte chemotactic protein 1. | | | | | |

---

290 Kidney Dis 2022;8:286–296
DOI: 10.1159/000524937
Mei/Jin/Zhao/Lu
moters were significantly lower in SLE patients with renal damage than in those without renal damage, indicating the potential for phenotype-specific differentially methylated CpG sites (DMCs). The canonical hypomethylated genes in lupus T cells also include CD40L, CD70, CD11a, etc. Specifically, inhibiting DNA methyltransferases in T cells [63], or administering DNA methyltransferase inhibitors [64], ameliorates proteinuria and restores glomerular morphology in lupus-like mice. The therapeutics used to target immune-related epigenetics in preclinical studies of LN are summarized in Table 2.

Like the GWASs, epigenome-wide association studies (EWASs) aim to identify epigenetic variation mainly in DMCs across the whole genome [65]. An EWAS associated with LN identified 19 DMCs in 18 genomic regions (mainly located in genes regulating the response to tissue hypoxia and IFN-mediated signaling); four sites in HIF3A, IFI44, and PRR4 were replicated from CD4+ T cells [66]. Patrick et al. [67] also observed similar results with more significant hypomethylation in the naïve T cells of lupus patients with renal involvement, especially for the IFN transcription factor IRF7. In addition to T cells, a 4-year longitudinal and trans-ancestral analysis of lupus patients reported that demethylation of a CpG site of GALNT18 gene in neutrophils was especially relevant to the development of LN [68].

RNAm has gained increasing importance in recent years, which includes N6-methyladenosine (m6A), N1-methyladenosine, N5-methylcytosine, pseudouridine (Ψ), etc. Similar to DNA methylation, it also requires a writer, eraser, and reader protein to guarantee this reversible process. The latest m6A study revealed that compared to the tubulointerstitial and whole kidney tissue, significant downregulation of m6A-related proteins was most obviously observed in glomeruli. METTL3, WTAP, YTHDC2, YTHDF1, FMR1, and FTO even comprised an m6A regulator signature to diagnose LN [69]. Pathway analysis demonstrated the involvement of activated NK cells, MHC-I-mediated antigen processing, cytokinesis, inflammation pathways, and interferon pathways. Mining the exact interplay between different RNAm proteins and immune responses may even develop into a productive direction for LN research.

**Histone Modification**

Histone modification is a covalent modification of small protein “tails” from the nucleosomes (containing two of each of the core histones: H2A, H2B, H3, and H4), thereby leading to chromatin compaction or decompaction and transcription alteration. In general, H3 and H4...
Acetylation (H3ac, H4ac) and H3 lysine4 di- or tri-methylation (H3K4me2/3) mediate chromatin decompaction and increased transcription, while H3 lysine9 di- or trimethylation (H3K9me2/3) and H3 lysine27 trimethylation (H3K27me3) lead to chromatin compaction and transcriptional repression [70, 71]. Studies of histone modification contributing to phenotypes of LN are rare. Urinary levels of histone deacetylase sirtuin-1 (Sirt1) were reported to be positively associated with disease activity in LN [72]. An inhibitor of Sirt1, resveratrol, was shown to ameliorate LN in MPL/lpr mice by deacetylating p65 NF-κB and increasing binding phosphor-p65 NF-κB to the Fcgr2b promoter, which results in the clearance of autoreactive B cells [73]. Alternatively, inhibitors of histone deacetylase 6 (HDAC6) and enhancers of zeste homolog 2, a histone-lysine N-methyltransferase, also performed well in treating LN in mice by modulating B cell and IFN-I pathways, individually, in lupus-like models [74, 75].

Noncoding RNAs

The human genome is widely transcribed, and most transcripts are ncRNAs. An ncRNA is a functional molecule that could not be translated into a protein. There are several subtypes of ncRNAs, such as microRNAs (miRNAs), long ncRNAs (IncRNAs), and circular RNAs (circRNAs). Abundant research has revealed the crucial roles of ncRNAs in autoimmune and inflammatory diseases, indicating that ncRNAs may not only serve as biomarkers but also as therapeutic agents or targets [70, 71, 76, 77].

miRNAs are ncRNAs with 21–23 bases, which function by binding to the messenger RNA 3′ untranslated region. Dicer, Argonaute-2, and other cellular factors such as RNA-induced silencing complexes are also observed to degrade messenger RNA [78]. Numerous studies have revealed that dysregulated miRNAs are involved in almost all the immune mechanisms mentioned above (shown in Table 3). Zhang et al. [79] found that B cell–related miR-15b in plasma can predict disease activity and low estimated glomerular filtration rate in SLE. Apart from miR-15b, elevated miR-148a significantly relates to renal relapses by influencing B-cell homeostasis [80]. Supplementation of miRNA analogs such as miR-654 [81], miR-16 [82], and miR-152 [83] or antagonists such as LNA-anti-miR-150 [84] reduced glomerulonephritis, IC deposition, and proteinuria in lupus-prone mice. LncRNA and circRNA are two types of newly defined ncRNAs that can function as a miRNA sponge or directly influence gene transcription and translation. Some researchers have found that aberrant levels of those ncRNAs serve as novel predictors of LN, such as Lnc-FOSB-1:1 in neutrophils [85] and circRNA_002453 in plasma [86]. Mechanically, ATAC sequencing identified IncRNA RP11-2B6.2 in renal biopsies can decrease the chromatin accessibility of SOCS1 of LN, which leads to positive feedback in IFN-I production [87]. In addition, circHLA-C [88] and hsa_circ_0123190 [89] can sponge fibrotic-related miRNA, miR150, and hsa-miR-483-3p, respectively. To date, their roles in the immune pathogenesis of LN have not yet been well studied.

| NcRNA               | Sample                           | Target                  | Function                                      | Reference(s) |
|---------------------|----------------------------------|-------------------------|-----------------------------------------------|--------------|
| miR-150, circHLA-C  | Renal biopsies                   | –                       | Fibrosis, inflammation, macrophages infiltration | [84, 88]     |
| lncRNA RP11-2B6.2   | Renal biopsies                   | SOCS1                   | IFN pathway                                   | [87]         |
| miR-130b            | Renal biopsies                   | Irf1                    | IFN pathway                                   | [106]        |
| miR-181a, lncRNA-p21| PBMCs, urine cells               | p21                     | Apoptosis                                     | [109]        |
| miR-10a-3p          | PBMCs                            | REG3A                   | Th17/Treg ratio, JAK2/STAT3 pathway           | [107]        |
| miR-16              | Plasma                           | DEC2                    | TLR4 signaling pathway                         | [82]         |
| miR-654             | PBMCs                            | MIF                     | AKT pathway                                   | [81]         |
| miR-155             | HRMCs                            | CXCR5                   | CXCR5-ERK pathway                             | [110]        |
| miR-223             | Human plasma, CD4⁺ T in MRL/lpr mice | S1PR1                  | T-cell migration and survival                  | [108]        |
| miR-148a            | B cells                          | BACH1, BACH2, PAX5      | B lymphocyte homeostasis                       | [80]         |

MIF, migration inhibitory factor; HRMC, human renal mesangial cell.

Crosstalk between Genetics and Epigenetics

Notably, although linkages between genetics and epigenetics are involved in lupus, most are aggregated in studies of SLE. Protein kinase C δ (PKCδ) is a crucial mol-
ecule in the pathogenesis of lupus, as its coding gene, PRKCD, is a susceptible locus for lupus. Mice lacking protein kinase C δ in T cells were shown to have lupus-like symptoms including renal damage with IgG deposition and decreased expression of DNA methyltransferase 1, possibly through its downstream ERK pathway signaling cascade [90]. In addition, genetics can also affect epigenetics directly. Several key enzymes in epigenetics [91], such as TET3 (encodes DNA demethylase), SMYD3 (encodes histone methyltransferase), and ncRNAs, such as lncRNA SLEAR [92], miR-146a [93, 94], have been reported to have SLE-associated SNPs, while miR-146a and miR-155 [95] were found to have LN-associated SNPs. Mechanically, take the miR-146a for example, with 3D chromatin structure and analysis, Hou et al. [93] demonstrated that the risk variant rs2431697, which is localized in the miR-146a enhancer, could resist to NF-κB binding, lower miR-146a expression, and eventually activate downstream IFN pathway in a monocyte-specific pathway.

**Conclusion**

In summary, genetic and epigenetic alterations are present in almost all aspects of the immunopathology behind LN. Currently, there are still limitations to studies of LN. For example, the genetic characteristics that may be associated with specific clinical manifestations of SLE are still understudied. Sanchez et al. [42] found that risk alleles in ITGAM and TNFSF4 were relevant to LN, FCGR2A was relevant to malar rash, and IL21 was relevant to hematological disorders. Therefore, more attention should be paid to the restricting characteristics of the enrolled SLE and LN patients to reduce false conclusions. In addition, besides aberrant immune responses, genetic alterations such as polymorphisms in adipokines [96], epigenetic alterations such as miR-422a [97], miR-26a, and miR-30b [98] in angiogenesis, lipid metabolism, fibrosis, and proliferation could also change the function of renal mesangial cells and tubular epithelial cells, influencing the progress of LN. Furthermore, in the case of LN, epigenetic research mostly focuses on ncRNAs, while studies of DNA and RNA modification and chromatin remodeling are lacking, even if lupus-related studies are abundant. Finally and perhaps most importantly, as So et al. [99] revealed that few references clarified miRNAs among different LN subclasses, the same was true with other immune-related genetic and epigenetic alterations. Hence, future studies that feature different LN subclasses or conversion between different subclasses seem necessary to elucidate the exact mechanism behind this challenging complication of SLE and to provide novel opinions for precision medicine.

**Conflict of Interest Statement**

The authors have no conflicts of interest to declare.

**Funding Sources**

This study was supported by the National Natural Science Foundation of China (No. 81874253), excellent postdoctoral innovative talents of Hunan province in 2020 (No. 2020RC2014), and the Natural Science Foundation of Hunan Province, China (No. 2021JJ40837).

**Author Contributions**

Xiaole Mei and Hui Jin drafted the manuscript; Qianjin Lu and Ming Zhao revised the manuscript.

**References**

1. Gisca E, Duarte L, Farinha F, Isenberg DA. Assessing outcomes in a lupus nephritis cohort over a 40-year period. Rheumatology. 2021;60(4):1814–22.
2. Moroni G, Vercelloni PG, Quaglini S, Gatto M, Gianfreda D, Sacchi L, et al. Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann Rheum Dis. 2018;77(9):1318–25.
3. Gasparotto M, Gatto M, Binda V, Doria A, Moroni G. Lupus nephritis: clinical presentations and outcomes in the 21st century. Rheumatology. 2020;59(Suppl 5):v39–51.
4. Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7.
5. Maria NI, Davidson A. Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy. Nat Rev Rheumatol. 2020;16(5):255–67.
6. Flores-Mendoza G, Sansón SP, Rodriguez-Castro S, Crispin JC, Rosetti F. Mechanisms of tissue injury in lupus nephritis. Trends Mol Med. 2018;24(4):364–78.
7. Bruschi M, Galetti M, Sinico RA, Moroni G, Bonanni A, Radice A, et al. Glomerular autoimmune multicomponents of human lupus nephritis in vivo (2): planted antigens. J Am Soc Nephrol. 2015;26(8):1905–24.
8. Stamataides EG, Tremblay ME, Bohm M, Crozet L, Bishk K, Kao D, et al. Immune monitoring of trans-endothelial transport by kidney-resident macrophages. Cell. 2016;166(4):991–1003.
9. Melki I, Allaerts I, Tessaudier N, Mailhot B, Cloutier N, Campbell RA, et al. FcgammaRIIA expression accelerates nephritis and increases platelet activation in systemic lupus erythematosus. Blood. 2020;136(25):2933–45.
20 Der E, Suryawanshi H, Morozov P, Kustagi Nishi H, Mayadas TN. Neutrophils in lupus DOI: 10.1159/000524937
294
2006.

23 Chen L, Wang YF, Liu L, Bielawka A, Ahmed R, Zhang H, et al. Genome-wide assessment of genetic risk for systemic lupus erythematosus and disease severity. *Hum Mol Genet*. 2020;29(10):1745–56.

24 Reid S, Haqberg N, Sandberg JK, Alessson A, Pucholt P, Sjowall C, et al. Interaction between the STAT4 rs11889394(T) risk allele and smoking confers increased risk of myocardial infarction and nephritis in patients with systemic lupus erythematosus. *Ann Rheum Dis*. 2021;80(9):1183–9.

25 Webber D, Cao J, Dominguez D, Gladman DD, Levy DM, Ng L, et al. Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE. *Rheumatology*. 2020;59(1):90–9.

26 Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Kohdiyar VK, et al. Gene map of the extended human MHC. *Nat Rev Genet*. 2004;5(12):889–99.

27 Taylor KE, Chung SA, Graham RR, Ortmann WA, Lee AT, Langeled CD, et al. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. *PLoS Genet*. 2011;7(2):e1001311.

28 Xu R, Li Q, Liu R, Shen J, Li M, Zhao M, et al. Association analysis of the MHC in lupus nephritis. *J Am Soc Nephrol*. 2017;28(11):3383–94.

29 Chung SA, Brown EE, Williams AH, Ramos PS, Berthier CC, Bhangale T, et al. Lupus nephritis susceptibility loci in women with systemic lupus erythematosus. *J Am Soc Nephrol*. 2014;25(12):2859–70.

30 Raj P, Rai E, Song R, Khan S, Misra AK, et al. Regulatory polymorphisms modulate the expression of HLA class II molecules and promote autoimmunity. *Elife*. 2016;5.

31 Teruel M, Alarcón-Riquelme ME. The genetic basis of systemic lupus erythematosus: what are the risk factors and what have we learned. *J Autoimmun*. 2016;74:161–75.

32 Niu Z, Zhang P, Tong Y. Value of HLA-DR genotype in systemic lupus erythematosus and lupus nephritis: a meta-analysis. *Int J Rheum Dis*. 2015;18(1):17–28.

33 Ramirez-Bello J, Cadena-Sandoval D, Mendez-Bruin D, Caceres-Munoz F, Ameczua-Guerra LM, et al. Tumor necrosis factor gene polymorphisms and systemic lupus erythematosus susceptibility or lupus nephritis in Mexican patients. *Immunol Res*. 2018;66(3):348–54.

34 Yang ZC, Xu F, Tang M, Xiong X. Association between TNF-alpha promoter -308 A/G polymorphism and systemic lupus erythematosus susceptibility: Case-Control Study and meta-analysis. *Scand J Immunol*. 2017;85(3):197–210.

35 Botto M, Dell’Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, et al. Homozygous CIQ1 deficiency causes glomerulonephritis associated with multiple apoptotic bodies. *Nat Genet*. 1998;19(1):56–9.

36 Liarski VM, Kavera N, Chang A, Brandt D, Yaney D, Talasnik N, et al. Cell distance mapping identifies functional T follicular helper cells in inflamed human renal tissue. *Sci Transl Med*. 2014;6(230):230ra46.

37 Nakamura B, Gray-McGuire C, Sestak AL, Gilkeson GS, Jacob CO, Merrill TF, et al. Evaluation of CIQ1 genetic region in minority racial groups of lupus. *Genes Immun*. 2009;10(5):517–24.

38 Radanova M, Vasilev V, Dimitrov T, Delisyska B, Tkononov V, Ivanova D. Association of rs172378 CIQ1 gene cluster polymorphism with lupus nephritis in Bulgarian patients. *Lupus*. 2015;24(3):280–9.

39 Mosaad YM, Hammad A, Fawzy Z, El-Refaei A, Tawhid Z, Hammad EM, et al. CIQ rs292001 polymorphism and CIQ antibodies in juvenile lupus and their relation to lupus nephritis. *Clin Exp Immunol*. 2015;182(1):23–34.

40 Freedman BI, Langeled CD, Andringa KK, Croaker JA, Williams AH, Garner NE, et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. *Arthritis Rheumatol*. 2016;64(2):390–6.

41 Muehlig AK, Gies S, Huber TB, Braun F. Colchicine and segmental glomerulosclerosis in viral infections. *Front Immunol*. 2021;12:800074.

42 Beckerman P, Bi-Karchin J, Park AS, Qiu C, Dummer PD, Soomro I, et al. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. *Nat Med*. 2017;23(4):429–38.

43 Sanchez E, Nadig A, Richardson BC, Freedman BI, Kaufman KM, Kelly JA, et al. Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. *Ann Rheum Dis*. 2011;70(10):1752–7.

44 Dong C, Ptece KS, Redden DT, Zhang K, Brown EE, Edberg JC, et al. Fcgamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis. *Rheumatology*. 2016;55(5):939–48.

45 Tsang ASMW, Nagelkerke SQ, Bultink IE, Geissler J, Tanck MW, Tacke CE, et al. Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis. *Rheumatology*. 2016;55(5):939–48.

46 Massarenti L, Enevold C, Damgaard D, Odum N, Nielsen CH, Jacobsen S. Peptidylarginine deiminase-4 gene polymorphisms are associated with systemic lupus erythematosus and lupus nephritis. *Scand J Rheumatol*. 2019;48(2):133–40.
Aberrant Immune-Related Genetic and Epigenetic Alterations in LN

49 Chen Y, Wang CM, Chen TD, Jan Wu YJ, Lin JC, Lu LY, et al. Interferon-lambda3/4 genetic variants and interferon-lambda3 serum levels are biomarkers of lupus nephritis and disease activity in Taiwanese. *Arthritis Res Ther*. 2018;20(1):193.

50 Xu WD, Fu L, Liu XY, Wang JM, Yuan ZC, Su LC, et al. Association between TLLA1 gene polymorphisms and systemic lupus erythematosus in a Chinese Han population. *J Cell Physiol*. 2019;234(12):2254–53.

51 Zhang YM, Zhou XJ, Cheng FJ, Qi YY, Hou P, Zhao MH, et al. Association of the IKZF15’UTR variant rs1456896 with lupus nephritis in a northern Han Chinese population. *Scand J Rheumatol*. 2017;46(3):210–4.

52 Chen GM, Feng CC, Ye QL, Tao JH, Li R, Peng H, et al. Association of P2XR7 gene polymorphisms with systemic lupus erythematosus in a Chinese population. *Mutagene- sis*. 2012;33(6):1045–9.

53 Joo YB, Park BL, Shin HD, Park SY, Kim I, Bae SC. Association of genetic polymorphisms in CD40 with susceptibility to SLE in the Korean population. *Rheumatology*. 2013;52(4):623–30.

54 Kim K, Bang SY, Joo YB, Kim T, Lee HS, Kang C, et al. Response to intravenous cyclophosphamide treatment for lupus nephritis associated with polymorphisms in the FCGR2B-FCRLA focus. *J Rheumatol*. 2016;43(6):1045–9.

55 Elloumi N, Fakhfakh R, Abida O, Hachicha H, Marzouk S, Fourati M, et al. RNA receptors, TLRL3 and TLRL7, are potentially associated with SLE clinical features. *Int J Immunogenet*. 2021;48(3):250–9.

56 Raaaf H, El Guindy N, Shahin RMH, Samy LA, El Refai RM. Toll-like receptor 7 gene single nucleotide polymorphisms and the risk for systemic lupus erythematosus: a case-control study. *Z Rheumatol*. 2018;77(5):416–20.

57 Zhou XJ, Lv JC, Cheng WR, Yu L, Zhao MH, Zhang H. Association of TLR9 gene polymorphisms with lupus nephritis in a Chinese Han population. *Clin Exp Rheumatol*. 2010;28(3):351–5.

58 Elloumi N, Fakhfakh R, Abida O, Ayadi L, Marzouk S, Hachicha H, et al. Relevant genetic polymorphisms and kidney expression of Toll-like receptor (TLR)-5 and TLR-9 in lupus nephritis. *Clin Immunol* 2017;190(3):328–39.

59 Wang CM, Chang SW, Wu YJ, Lin JC, Ho HH, Chou TC, et al. Genetic variations in Toll-like receptor (TLRs) 3/7/8 are associated with systemic lupus erythematosus in a Taiwanese population. *Sci Rep*. 2014;4:3792.

60 Tian J, Ma Y, Li J, Chen H, Wang DG, Feng CC, et al. The TLR7 7926A>G polymorphism is associated with susceptibility to systemic lupus erythematosus. *Mol Med Rep*. 2012;6(1):105–10.

61 Garcia-Artiz H, Velaquez-Cruz R, Espinosa-Rosales F, Jimenez-Morales S, Baca V, Orozco L. Association of TLR7 copy number variation with susceptibility to childhood-onset systemic lupus erythematosus in Mexican population. *Ann Rheum Dis*. 2010;69(10):1841–5.

62 Wardowska A, Komorniczak M, Bullo-Piontecka B, Debska-Sliżewieś MA, Pikuła M. Transcriptomic and epigenetic alterations in dendritic cells correspond with chronic kidney disease in lupus nephritis. *Front Immunol*. 2019;10:2026.

63 Li H, Tsokos MG, Bickerton S, Sharabi A, Li Y, Moulton VR, et al. Precision DNA demethylation ameliorates disease in lupus-prone mice. *J Clin Invest*. 2018;131(10):128080.

64 Perper SJ, Westmoreland SV, Karman J, Tomery S, Reagal J, Wang R, et al. Treatment with a CD40 antagonist antibody reverses severe proteinuria and loss of saliva production and restores glomerular morphology in murine systemic lupus erythematosus. *J Immunol*. 2019;203(1):58–75.

65 Imgenberg-Kreuz J, Carlson Almlof J, Leonard D, Alexson A, Nordmark G, Eloranta ML, et al. DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus. *Ann Rheum Dis*. 2018;77(5):736–43.

66 Mok A, Solomon O, Nayak RR, Jeffries MA, Mollitt DL, et al. Genome-wide profiling identifies associations between lupus nephritis and differential methylation of genes regulating tissue hypoxia and type 1 interferon responses. *Lupus Sci Med*. 2016;3(1):1000183.

67 Coit P, Renauer P, Jeffries MA, Mollitt DL, et al. DNA methylation changes in naive CD4+ T cells. *J Autoimmun*. 2015;61:29–35.

68 Coit P, Orfiz-Lopez J, Lewis EE, McCune WJ, Maksimowicz-McKinnon K, et al. Renal involvement in lupus is characterized by unique DNA methylation changes in naive CD4+ T cells. *J Autoimmun*. 2015;61:29–35.

69 Mok A, Solomon O, Nayak RR, Jeffries MA, Mollitt DL, et al. Genome-wide profiling identifies associations between lupus nephritis and differential methylation of genes regulating tissue hypoxia and type 1 interferon responses. *Lupus Sci Med*. 2016;3(1):1000183.

70 Coit P, Renauer P, Jeffries MA, Mollitt DL, et al. DNA methylation changes in naive CD4+ T cells. *J Autoimmun*. 2015;61:29–35.

71 Wardowska A. The epigenetic face of lupus: understanding the structure and function of small RNAs. *Nat Rev Rheumatol*. 2007;3(1):23–36.

72 Zhang H, Huang X, Ye L, Guo G, Li X, Chen C, et al. B cell-related circulating microRNAs with the potential value of biomarkers in the differential diagnosis, and distinguishing between the disease activity and lupus nephritis for systemic lupus erythematosus. *Front Immunol*. 2018;9:1473.

73 Yap DH, Yung S, Lee P, Yam IYL, Tam C, Tang C, et al. B cell subsets and cellular signatures and disease relapse in lupus nephritis. *Front Immunol*. 2020;11:1732.

74 Tu Y, Guo R, Li J, Wang S, Leng L, Deng J, et al. miRNA regulation of MIF in SLE and attenuation of murine lupus nephritis with miR-654. *Front Immunol*. 2019;10:2229.

75 Qi H, Cao Q, Liu Q. MicroRNA-16 directly binds to DEC2 and inactivates the TLR4 signaling pathway to inhibit lupus nephritis-induced kidney tissue hyperplasia and mesangial cell proliferation. *Int Immunopharmacophysiol*. 2020;88:106859.

76 Zheng J, Guo R, Tang Y, Fu Q, Chen J, Wu L, et al. miR-152 attenuates the severity of lupus nephritis through the downregulation of macrophage migration inhibitory factor (MIF)-induced expression of COL1A1. *Front Immunol*. 2019;10:158.

77 Luan J, Fu J, Chen C, Jiao C, Kong W, Zhang Y, et al. LNA-anti-miR-150 ameliorated kidney injury of lupus nephritis by inhibiting renal fibrosis and macrophage infiltration. *Arthritis Res Ther*. 2019;21(1):276.

78 Cai B, Cai J, Yin Z, Jiang X, Yao C, Ma J, et al. Long non-coding RNA expression profiles in neutrophils reveal potential biomarker for prediction of renal involvement in SLE patients. *Rheumatology*. 2021;56(4):1734–46.

79 Ouyang Q, Huang Q, Jiang Z, Zhao J, Shi GP, Yang M. Using plasma circRNA_002453 as a novel biomarker in the diagnosis of lupus nephritis. *Mol Immunol*. 2018;101:531–8.

80 Liao Z, Ye Z, Xue Z, Wu L, Ouyang Y, Yao C, et al. Identification of renal long non-coding RNA RP11-2B6.2 as a positive regulator of type 1 interferon signaling pathway in lupus nephritis. *Front Immunol*. 2019;10:975.

Kidney Dis 2022;8:286–296 DOI: 10.1159/000524937
88  Luan J, Jiao C, Kong W, Fu J, Qu W, Chen Y, et al. circHLA-C plays an important role in lupus nephritis by splicing miR-150. Mol Ther Nucleic Acids. 2018;10:245–53.
89  Zhang C, Gao C, Di X, Cui S, Liang W, Sun W, et al. Hsa_circ_0123190 acts as a competitive endogenous RNA to regulate APLNR expression by sponging hsa-miR-483-3p in lupus nephritis. Arthritis Res Ther. 2021;23(1):24.
90  Gorelik G, Sawalha AH, Patel D, Johnson K, Richardson B. T cell PKCδ kinase inactivation induces lupus-like autoimmunity in mice. Clin Immunol. 2015;158(2):193–203.
91  Oparina N, Martinez-Bueno M, Alarcon-Riquelme ME. An update on the genetics of systemic lupus erythematosus. Curr Opin Rheumatol. 2019;31(6):659–68.
92  Fan Z, Chen X, Liu L, Zhu C, Xu J, Yin X, et al. Association of the polymorphism rs13259960 in SLEAR with predisposition to lupus nephritis and no association of its receptor CCR2 -64 V/I polymorphism with lupus nephritis. J Rheumatol. 2015;67(9):2415–26.
93  So BYF, Yap DYH, Chan TM. MicroRNAs in lupus nephritis-role in disease pathogenesis and clinical applications. Int J Mol Sci. 2021;22(19):10737.
94  Hou G, Harley ITW, Lu X, Zhou T, Xu N, Yao C, et al. SLE non-coding genetic risk variant determines the epigenetic dysfunction of an immune cell specific enhancer that controls disease-critical microRNA expression. Nat Commun. 2021;12(1):135.
95  Fouda ME, Nour El Din DM, Mahgoub MY, Elashkar AE, Abdel Halim WA. Genetic variants of microRNA-146a gene: an indicator of systemic lupus erythematosus susceptibility, lupus nephritis, and disease activity. Mol Biol Rep. 2020;47(10):7459–66.
96  Mohamed SR, Shaker OG, Mohammed AA, Fouad NA, Hussein HA, Ahmed NA, et al. Impact of miR-155 (rs767649 A>T) and miR-146a (rs57095329 A>G) polymorphisms in system lupus erythematosus susceptibility in an Egyptian cohort. Eur Rev Med Pharmacol Sci. 2021;25(3):1425–35.
97  Zhang TP, Li HM, Li R, Zhang Q, Fan YG, Li XM, et al. Association of omentin-1, adiponectin, and resistin genetic polymorphisms with systemic lupus erythematosus in a Chinese population. Int Immunopharmacol. 2020;83:106343.
98  Krasoudaki E, Drakos E, Sinatka V, et al. MicroRNA analysis of renal biopsies in human lupus nephritis demonstrates up-regulated miR-422a driving reduction of kallikrein-related peptidase 4. Nephrol Dial Transplant. 2016;31(10):1676–86.
99  Costa-Reis P, Russo PA, Zhang Z, Colonna L, Maurer K, Gallucci S, et al. The role of microRNAs and human epidermal growth factor receptor 2 in proliferative lupus nephritis. Arthritis Rheumatol. 2015;67(9):2415–26.
100 Malafontes P, Vieira JM Jr, Pereira AC, Krieger JE, Barros RT, Woronik V. Association of the MCP-1 -2518 A/G polymorphism and no association of its receptor CCR2 -64 V/I polymorphism with lupus nephritis. Rheumatol. 2010;38(7):776–82.
101 He CF, Liu YS, Cheng YL, Gao JP, Pan TM, Han JW, et al. TNIP1, SLC15A4, ETS1, RasGRP3 and IKZF1 are associated with clinical features of systemic lupus erythematosus in a Chinese Han population. Lupus. 2010;19(10):1181–6.
102 Zhang F, Wang YF, Zhang Y, Lin Z, Cao Y, Zhang H, et al. Independent Replication on Genome-Wide Association Study signals identifies IRF3 as a novel locus for systemic lupus erythematosus. Front Genet. 2020;11:600.
103 Rovin BH, Lu L, Zhang X. A novel interleukin-8 polymorphism is associated with severe systemic lupus erythematosus nephritis. Kidney Int. 2002;62(1):261–5.
104 Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest. 2003;111(4):539–52.
105 White CA, Pone EL, Lam T, Tac C, Hayama KL, Li G, et al. Histone deacetylase inhibitors upregulate B cell microRNAs that silence AID and Blimp-1 expression for epigenetic modulation of antibody and autoantibody responses. J Immunol. 2014;193(12):5933–50.
106 Han X, Wang Y, Zhang X, Qin Y, Qu B, Wu L, et al. MicroRNA-130b ameliorates murine lupus nephritis through targeting the type I interferon pathway on renal mesangial cells. Arthritis Rheumatol. 2016;68(9):2232–43.
107 You G, Cao H, Yan L, He P, Wang Y, Liu B, et al. MicroRNA-10a-3p mediates Th17/Treg cell balance and improves renal injury by inhibiting REG3A in lupus nephritis. Int Immunopharmacol. 2020;88:106891.
108 Hiramatsu-Asano S, Sunahori-Watanabe K, Zeggari S, Katsuyama E, Mukai T, Morita Y, et al. Deletion of Mir223 exacerbates lupus nephritis by targeting S1pr1 in Fas(lpr/lpr) mice. Front Immunol. 2020;11:616141.
109 Chen YC, Kuo PY, Chou YC, Chong HE, Hsieh YT, Yang ML, et al. Up-regulated expression of pro-apoptotic long noncoding RNA lincRNA-p21 with enhanced cell apoptosis in lupus nephritis. Int J Mol Sci. 2020;21(2):301.
110 Kong J, Li L, Lu Z, Song J, Yan J, Yang J, et al. MicroRNA-155 suppresses mesangial cell proliferation and TGF-beta1 production via inhibiting CXCR5-ERK signaling pathway in Lupus Nephritis. Inflammation. 2019;42(1):255–63.
111 Yang W, Zhao M, Hirankar N, Lau CS, Mok CC, Chan TM, et al. ITGAM is associated with disease susceptibility and renal nephritis of systemic lupus erythematosus in Hong Kong Chinese and Thai. Hum Mol Genet. 2009;18(11):2063–70.